查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球藥品再利用市場，到 2030 年的預測：按類型、治療領域和地區分類的全球分析
市場調查報告書
商品編碼
1372003

全球藥品再利用市場，到 2030 年的預測：按類型、治療領域和地區分類的全球分析

Drug Repurposing Market Forecasts to 2030 - Global Analysis By Type (Target-Centric Approach, Disease-Centric Approach and Drug-Centric Approach), Therapeutic Area and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球藥物再利用市場規模為 387 億美元，預計在預測期內年複合成長率為 7.4%，到 2030 年將達到 639 億美元。

藥物再利用（也稱為藥物重新定位或藥物重新分析）是藥物研究和開發中使用的一種技術，其中研究用於治療一種疾病或病理的現有藥物並用於治療其他疾病。它用於治療病理。與開發全新藥物相比，該策略具有更短的開發時間、更低的成本以及更好地了解藥物的安全性等優勢。透過研究作用機制、藥理學特徵以及治療各種疾病和病症的潛力，研究人員可以發現已核准藥物的新治療用途。

藥品短缺和醫療需求未被滿足

使用重新調整用途的藥物來治療被忽視的熱帶疾病 (NTD) 和罕見疾病是非常有益的。開發新藥很困難，因為針對這些疾病的研究和開發很少。為該患者族群提供替代療法的一個可行策略是藥物再利用。由於生產問題、產品撤回、供應鏈中斷等原因，某些藥品可能會出現短缺。將其他現有藥物重新用於類似的適應症可以幫助消除藥物短缺並確保持續獲得​​救命藥物。

智慧財產權保護力道不夠

智慧財產權保護不充分或不存在可能會阻礙製藥公司和投資者參與藥物再利用配合措施。如果沒有專屬行銷權和收益潛力，進行再利用研究的經濟誘因就會減少，競爭也會加劇，因為多個組織可能會針對同一種藥物進行再利用。多種版本的再利用藥物競爭市場佔有率，可能會導致市場分散化。

成本和時間效率

開發一種全新的藥物，從藥物研發到上市核准，可能非常昂貴，有時高達數十億美元。另一方面，透過利用具有已知安全性的現有物質，藥物重複使用可以顯著降低研究成本。傳統藥物開發從研究開始到監管核准可能需要 10 多年的時間。另一方面，拖曳重新利用通常會導致更快的開發時間。研究人員無需將時間花在漫長的早期藥物研發過程上，而是可以專注於臨床評估和監管核准，節省成本和時間。這將增加該技術的採用並進一步提振市場。

市場競爭

由於激烈的競爭，藥物再利用市場可能會變得分散。許多營業單位可能會重複使用相同的藥物，因為它效率低、成本高昂，並且會減慢開發過程。這可能會導致重複配合措施、資源分散以及相同藥物再利用的臨床試驗的重複和重複。在競爭激烈的情況下，製藥公司、學術機構和研究團體之間的合作可能會受到抑制。這可能會導致資訊、資源和專業知識的共用變得困難，並導致開發緩慢。

COVID-19 的影響

COVID-19大流行迫切需要有效的治療方法和疫苗接種。由於藥物的重新利用，研究人員能夠快速研究現有的可能治療該病毒及其症狀的藥物。快速反應對於解決公共衛生問題至關重要。重新利用藥物治療 COVID-19 的有效性已成為多項研究的主題。這些研究測試了抗病毒藥物、發炎劑和改造疫苗。這些發現對建議和治療指南具有影響。

以目標為中心的進場領域預計將在預測期內達到最大

由於藥物再利用中以標靶為中心的方法側重於根據與疾病相關的特定分子標靶和途徑來發現和創造治療方法，因此以標靶為中心的方法部分預計將出現良好的成長。此策略首先要了解疾病的生物學原理，然後尋找可以影響已發現的標靶或途徑的現有藥物或化學物質。以目標為中心的方法可以鑒定疾病生物標記，可用於患者分層、治療反應監測和疾病進展預測。

預計領域在預測期內將經歷最高的年複合成長率

由於這些藥物具有經過驗證的安全實績和作用機制，因此預計腫瘤學領域在預測期內將以最高的年複合成長率成長。腫瘤學領域的重新配合措施可以集中在發現與癌症發展和擴散相關的新分子標靶和途徑。這可能會導致對可以改變這些目標的現有藥物的探索。已經啟動了幾項臨床試驗，以確定重新利用的藥物是否能有效治療各種腫瘤。此外，這些研究對於證明新用途藥物的有效性和安全性至關重要。一些藥物在未能證明其原始適應症的功效後，已被有效地重新用於治療癌症，為臨床使用提供了第二次機會。

比最大的地區

預計北美將在預測期內佔據最大的市場佔有率，因為它是蓬勃發展的製藥業的所在地，並且大型製藥企業正在資助藥物再利用的研究。這些公司通常擁有長期臨床試驗和重新利用藥物商業化所需的資產和專業知識。合作研究在北美很常見，政府、企業和學術機構經常就重新利用計畫進行合作。合作研究有助於調動資源和知識。此外，資金由美國國立衛生美國(NIH) 等美國政府機構提供。這種支持激發了該領域的創造力。

複合年複合成長率最高的地區

預計歐洲在預測期內的年複合成長率最高。這是因為歐洲擁有世界上最大、成長最快的藥物再利用市場。對負擔得起的藥物開發的需求、不斷增加的患者數量以及大量的研發支出推動了市場的發展。歐洲擁有多家著名的學術機構、製藥公司和研究機構，它們積極致力於藥物的再利用。歐洲藥品管理局 (EMA) 等歐洲法規機構可以核准再利用藥物。該地區有利的藥物再法規環境促進了再利用藥物的開發和市場開拓。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球藥品再利用市場：依類型

  • 以目標為中心的方法
  • 以疾病為中心的方法
  • 以藥物為中心的方法

第6章 全球藥品再利用市場：依治療領域

  • 中樞神經系統疾病
  • 腫瘤學
  • 神經退化性疾病
  • 其他治療領域

第7章 全球藥品再利用市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Excelra
  • ChemBio Discovery, Inc.
  • Celentyx Ltd
  • Algernon Pharmaceuticals
  • Biovista
  • Lantern Pharma, Inc.
  • Fios Genomics
  • Segue Therapeutics, LLC
  • Paradigm Biopharmaceuticals Ltd
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Sosei Group Corporation
  • Centene Corporation（Health Net LLC）
  • SOM Innovation Biotech SL
  • Recursion Pharmaceuticals Inc.
  • Atomwise Inc.
  • Healx
  • NuMedii Inc.
Product Code: SMRC24059

According to Stratistics MRC, the Global Drug Repurposing Market is accounted for $38.7 billion in 2023 and is expected to reach $63.9 billion by 2030 growing at a CAGR of 7.4% during the forecast period. Drug repurposing, often referred to as drug repositioning or drug reprofiling, is a method used in pharmaceutical research and development whereby already-existing medications that were created to treat one disease or condition are examined and then used to treat other illnesses or conditions. Shorter development times, lower costs, and a better grasp of the drug's safety profile are just a few benefits this strategy has over the creation of totally new pharmaceuticals. By examining the mechanisms of action, pharmacological characteristics, and potential to treat various diseases or ailments, researchers can discover novel therapeutic applications for already approved medications.

Market Dynamics:

Driver:

Drug scarcity and unmet medical needs

Using repurposed medications to treat neglected tropical diseases (NTDs) and unusual diseases is very beneficial. It is difficult to produce new medications for these illnesses since little research and development is frequently given to them. A viable strategy for offering therapy alternatives to these patient populations is medication repurposing. Specific medicine shortages may occasionally occur as a result of production problems, product withdrawal, or supply chain interruptions. Drug shortages can be reduced and sustained access to life-saving medicines can be ensured by repurposing other currently available medications for comparable indications owing to encouraging growth of the market.

Restraint:

Insufficient protection for intellectual property

Pharmaceutical firms and investors can be discouraged from taking part in initiatives at medication repurposing if intellectual property protection is inadequate or non-existent. The financial incentives to do repurposing research decline in the absence of the possibility of exclusive selling rights and revenue and several organizations may target the same medicine for repurposing, increasing rivalry. Multiple versions of repurposed medications may compete for market share, fragmenting the market.

Opportunity:

Cost and time efficiency

A fully new drug's development may be extremely expensive, sometimes costing billions of dollars, from discovery through market approval. On the other side, drug repurposing makes use of already-existing substances with known safety profiles, drastically cutting the cost of research. From beginning research to regulatory clearance, traditional medication development might need more than ten years. Drug repurposing, on the other hand, typically has faster development times. Instead of spending time on the time-consuming early drug discovery process, researchers may concentrate on clinical assessment and regulatory approval which in turn saves coast and time. This leads to increased adoption to this method and further propels the market.

Threat:

Market rivalry

The market for drug repurposing may become fragmented as a result of intense rivalry. Inefficient, expensive, and perhaps slowing down the development process, many entities may target the same medications for repurposing. This can result in duplicated efforts and a spread of resources as well as duplicate or overlapping clinical studies for the same repurposed drug. Collaboration between pharmaceutical corporations, academic institutions, and research groups may be discouraged in highly competitive situations. This may slow down development by making it more difficult to share information, resources, and expertise.

COVID-19 Impact

Effective treatments and vaccinations are urgently needed because to the COVID-19 pandemic. Researchers were able to swiftly examine current medications with the potential to tackle the virus and its symptoms thanks to drug repurposing. In order to resolve the public health situation, an expedited reaction time was essential. The effectiveness of repurposed medications in treating COVID-19 had been the subject of several research investigations. Antivirals, anti-inflammatories, and repurposed vaccinations were all tested in these studies. These studies' findings have an impact on recommendations and treatment guidelines.

The target-centric approach segment is expected to be the largest during the forecast period

The target-centric approach segment is estimated to have a lucrative growth, as target-centric approach in drug repurposing focuses on finding and creating treatments based on specific molecular targets or pathways linked to a disease. In this strategy, the biology of a disease is first understood, and then existing medications or chemicals that can influence the discovered target or pathway are sought for. Target-centric methods can result in the identification of disease biomarkers that can be applied to patient stratification, therapy response monitoring, and disease progression prediction.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is anticipated to witness the highest CAGR growth during the forecast period, because these medications have proven safety records and modes of action. Oncology repurposing initiatives can concentrate on discovering fresh molecular targets or pathways linked to the emergence and spread of cancer. Exploring already available medications that can modify these targets may result from this. To determine if repurposed medications are effective in treating different tumors, several clinical trials have been launched. Moreover, these studies are crucial for proving the effectiveness and safety of repurposed medications. Some medications have been effectively repurposed for cancer after failing to demonstrate efficacy for their original indications, providing them a second opportunity for clinical usage.

Region with largest share:

North America is projected to hold the largest market share during the forecast period because the pharmaceutical trade in North America is thriving, and leading pharmaceutical firms fund research on drug repurposing. These businesses frequently have the assets and know-how necessary to carry out lengthy clinical trials and commercialize repurposed medications. In North America, collaboration is typical, with government, business, and academic institutions frequently collaborating on repurposing initiatives. Collaboration helps to combine resources and knowledge. Moreover, funding is provided by US government organizations like the National Institutes of Health (NIH). The field's creativity is sparked by this backing.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period; owing to the world's biggest and fastest-growing marketplaces for medication repurposing is found in Europe. The market is fuelled by things like the demand for affordable medication development, an increase in the patient population, and significant expenditure in R&D. There are several notable academic institutions, pharmaceutical firms, and research facilities in Europe that are actively engaged in medication repurposing initiatives. Repurposed medicine approval is made possible by European regulatory organizations like the European Medicines Agency (EMA). The development and market accessibility of repurposed medications are made easier by the region's favourable regulatory environment for drug repurposing.

Key players in the market:

Some of the key players profiled in the Drug Repurposing Market include: Excelra, ChemBio Discovery, Inc., Celentyx Ltd, Algernon Pharmaceuticals, Biovista, Lantern Pharma, Inc., Fios Genomics, Segue Therapeutics, LLC, Paradigm Biopharmaceuticals Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd, Sosei Group Corporation, Centene Corporation (Health Net LLC, SOM Innovation Biotech S.L., Recursion Pharmaceuticals Inc., Atomwise Inc., Healx and NuMedii Inc.

Key Developments:

In October 2023, Novartis present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

In April 2023, Excelra, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA.

In April 2023, Biosynex Completes Acquisition of Chembio Diagnostics, Inc., The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers

Types Covered:

  • Target-Centric Approach
  • Disease-Centric Approach
  • Drug-Centric Approach

Therapeutic Areas Covered:

  • CNS Disorders
  • Oncology
  • Neurodegenerative Diseases
  • Other Therapeutic Areas

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Repurposing Market, By Type

  • 5.1 Introduction
  • 5.2 Target-Centric Approach
  • 5.3 Disease-Centric Approach
  • 5.4 Drug-Centric Approach

6 Global Drug Repurposing Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 CNS Disorders
  • 6.3 Oncology
  • 6.4 Neurodegenerative Diseases
  • 6.5 Other Therapeutic Areas

7 Global Drug Repurposing Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Excelra
  • 9.2 ChemBio Discovery, Inc.
  • 9.3 Celentyx Ltd
  • 9.4 Algernon Pharmaceuticals
  • 9.5 Biovista
  • 9.6 Lantern Pharma, Inc.
  • 9.7 Fios Genomics
  • 9.8 Segue Therapeutics, LLC
  • 9.9 Paradigm Biopharmaceuticals Ltd
  • 9.10 Novartis AG
  • 9.11 Teva Pharmaceutical Industries Ltd
  • 9.12 Sosei Group Corporation
  • 9.13 Centene Corporation (Health Net LLC
  • 9.14 SOM Innovation Biotech S.L.
  • 9.15 Recursion Pharmaceuticals Inc.
  • 9.16 Atomwise Inc.
  • 9.17 Healx
  • 9.18 NuMedii Inc.

List of Tables

  • Table 1 Global Drug Repurposing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 4 Global Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 5 Global Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 6 Global Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 7 Global Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 8 Global Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 9 Global Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 10 Global Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 14 North America Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 15 North America Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 16 North America Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 17 North America Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 18 North America Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 19 North America Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 20 North America Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 21 North America Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 22 North America Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 23 North America Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 24 Europe Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 Europe Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 Europe Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 27 Europe Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 28 Europe Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 29 Europe Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 30 Europe Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 31 Europe Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 32 Europe Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 33 Europe Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 34 Asia Pacific Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 35 Asia Pacific Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 36 Asia Pacific Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 37 Asia Pacific Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 38 Asia Pacific Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 39 Asia Pacific Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 40 Asia Pacific Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 41 Asia Pacific Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 42 Asia Pacific Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 43 Asia Pacific Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 44 South America Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 45 South America Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 46 South America Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 47 South America Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 48 South America Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 49 South America Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 50 South America Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 51 South America Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 52 South America Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 53 South America Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 54 Middle East & Africa Drug Repurposing Market Outlook, By Country (2021-2030) ($MN)
  • Table 55 Middle East & Africa Drug Repurposing Market Outlook, By Type (2021-2030) ($MN)
  • Table 56 Middle East & Africa Drug Repurposing Market Outlook, By Target-Centric Approach (2021-2030) ($MN)
  • Table 57 Middle East & Africa Drug Repurposing Market Outlook, By Disease-Centric Approach (2021-2030) ($MN)
  • Table 58 Middle East & Africa Drug Repurposing Market Outlook, By Drug-Centric Approach (2021-2030) ($MN)
  • Table 59 Middle East & Africa Drug Repurposing Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 60 Middle East & Africa Drug Repurposing Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 61 Middle East & Africa Drug Repurposing Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 62 Middle East & Africa Drug Repurposing Market Outlook, By Neurodegenerative Diseases (2021-2030) ($MN)
  • Table 63 Middle East & Africa Drug Repurposing Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)